First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 24 2025
0mins
Source: Globenewswire
CLARITY Trial Enrollment: Aclarion, Inc. has enrolled the first patient in its CLARITY trial at the Texas Back Institute, aimed at evaluating the effectiveness of Nociscan in improving surgical outcomes for chronic low back pain through advanced diagnostic techniques.
Nociscan Technology: Nociscan utilizes Magnetic Resonance Spectroscopy and AI to help physicians identify painful discs in the lumbar spine, potentially enhancing treatment strategies for the 266 million people globally suffering from degenerative spine disease and low back pain.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
